Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells

Robert A. Adair, Karen J. Scott, Sheila Fraser, Fiona Errington-Mais, Hardev Pandha, Matt Coffey, Peter Selby, Graham P. Cook, Richard Geoffrey Vile, Kevin J. Harrington, Giles Toogood, Alan A. Melcher

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Reovirus is a promising oncolytic virus, acting by both direct and immune-mediated mechanisms, although its potential may be limited by inactivation after systemic delivery. Our study addressed whether systemically delivered reovirus might be shielded from neutralising antibodies by cell carriage and whether virus-loaded blood or hepatic innate immune effector cells become activated to kill colorectal cancer cells metastatic to the liver in human systems. We found that reovirus was directly cytotoxic against tumour cells but not against fresh hepatocytes. Although direct tumour cell killing by neat virus was significantly reduced in the presence of neutralising serum, reovirus was protected when loaded onto peripheral blood mononuclear cells, which may carry virus after intravenous administration in patients. As well as handing off virus for direct oncolytic killing, natural killer (NK) cells within reovirus-treated blood mononuclear cells were stimulated to kill tumour targets, but not normal hepatocytes, in a Type I interferon-dependent manner. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumour cells when activated by reovirus. Hence, intravenous reovirus may evade neutralisation by serum via binding to circulating mononuclear cells, and this blood cell carriage has the potential to investigate both direct and innate immune-mediated therapy against human colorectal or other cancers metastatic to the liver. What's new? Reovirus can deliver a double whammy to cancer: it hunts down and destroys ras-activated tumor cells, and it can also fire up the immune system against the tumor. The immune system, however, is a fickle ally; in addition to attacking tumor cells, an efficient immune response also rids the body of reovirus, hindering therapy. This study investigated whether therapeutic reovirus could be shielded from immune assault. They showed that loading reovirus onto blood mononuclear cells provides safe transportation to target cells, in this case, colorectal tumor cells, and the reovirus-loaded immune cells themselves also launch an attack against tumor cells. Reovirus appears to be a promising new avenue for cancer treatment.

Original languageEnglish (US)
Pages (from-to)2327-2338
Number of pages12
JournalInternational Journal of Cancer
Volume132
Issue number10
DOIs
StatePublished - May 15 2013

Fingerprint

Colorectal Neoplasms
Liver
Neoplasms
Blood Cells
Oncolytic Viruses
Viruses
Natural Killer Cells
Hepatocytes
Immune System
Interferon Type I
Therapeutics
Neutralizing Antibodies
Serum
Intravenous Administration

Keywords

  • colorectal liver metastases
  • interferon-dependent
  • NK cells
  • reovirus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adair, R. A., Scott, K. J., Fraser, S., Errington-Mais, F., Pandha, H., Coffey, M., ... Melcher, A. A. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. International Journal of Cancer, 132(10), 2327-2338. https://doi.org/10.1002/ijc.27918

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. / Adair, Robert A.; Scott, Karen J.; Fraser, Sheila; Errington-Mais, Fiona; Pandha, Hardev; Coffey, Matt; Selby, Peter; Cook, Graham P.; Vile, Richard Geoffrey; Harrington, Kevin J.; Toogood, Giles; Melcher, Alan A.

In: International Journal of Cancer, Vol. 132, No. 10, 15.05.2013, p. 2327-2338.

Research output: Contribution to journalArticle

Adair, RA, Scott, KJ, Fraser, S, Errington-Mais, F, Pandha, H, Coffey, M, Selby, P, Cook, GP, Vile, RG, Harrington, KJ, Toogood, G & Melcher, AA 2013, 'Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells', International Journal of Cancer, vol. 132, no. 10, pp. 2327-2338. https://doi.org/10.1002/ijc.27918
Adair, Robert A. ; Scott, Karen J. ; Fraser, Sheila ; Errington-Mais, Fiona ; Pandha, Hardev ; Coffey, Matt ; Selby, Peter ; Cook, Graham P. ; Vile, Richard Geoffrey ; Harrington, Kevin J. ; Toogood, Giles ; Melcher, Alan A. / Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. In: International Journal of Cancer. 2013 ; Vol. 132, No. 10. pp. 2327-2338.
@article{d5deb9222dac438f99ad361d1875b590,
title = "Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells",
abstract = "Reovirus is a promising oncolytic virus, acting by both direct and immune-mediated mechanisms, although its potential may be limited by inactivation after systemic delivery. Our study addressed whether systemically delivered reovirus might be shielded from neutralising antibodies by cell carriage and whether virus-loaded blood or hepatic innate immune effector cells become activated to kill colorectal cancer cells metastatic to the liver in human systems. We found that reovirus was directly cytotoxic against tumour cells but not against fresh hepatocytes. Although direct tumour cell killing by neat virus was significantly reduced in the presence of neutralising serum, reovirus was protected when loaded onto peripheral blood mononuclear cells, which may carry virus after intravenous administration in patients. As well as handing off virus for direct oncolytic killing, natural killer (NK) cells within reovirus-treated blood mononuclear cells were stimulated to kill tumour targets, but not normal hepatocytes, in a Type I interferon-dependent manner. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumour cells when activated by reovirus. Hence, intravenous reovirus may evade neutralisation by serum via binding to circulating mononuclear cells, and this blood cell carriage has the potential to investigate both direct and innate immune-mediated therapy against human colorectal or other cancers metastatic to the liver. What's new? Reovirus can deliver a double whammy to cancer: it hunts down and destroys ras-activated tumor cells, and it can also fire up the immune system against the tumor. The immune system, however, is a fickle ally; in addition to attacking tumor cells, an efficient immune response also rids the body of reovirus, hindering therapy. This study investigated whether therapeutic reovirus could be shielded from immune assault. They showed that loading reovirus onto blood mononuclear cells provides safe transportation to target cells, in this case, colorectal tumor cells, and the reovirus-loaded immune cells themselves also launch an attack against tumor cells. Reovirus appears to be a promising new avenue for cancer treatment.",
keywords = "colorectal liver metastases, interferon-dependent, NK cells, reovirus",
author = "Adair, {Robert A.} and Scott, {Karen J.} and Sheila Fraser and Fiona Errington-Mais and Hardev Pandha and Matt Coffey and Peter Selby and Cook, {Graham P.} and Vile, {Richard Geoffrey} and Harrington, {Kevin J.} and Giles Toogood and Melcher, {Alan A.}",
year = "2013",
month = "5",
day = "15",
doi = "10.1002/ijc.27918",
language = "English (US)",
volume = "132",
pages = "2327--2338",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells

AU - Adair, Robert A.

AU - Scott, Karen J.

AU - Fraser, Sheila

AU - Errington-Mais, Fiona

AU - Pandha, Hardev

AU - Coffey, Matt

AU - Selby, Peter

AU - Cook, Graham P.

AU - Vile, Richard Geoffrey

AU - Harrington, Kevin J.

AU - Toogood, Giles

AU - Melcher, Alan A.

PY - 2013/5/15

Y1 - 2013/5/15

N2 - Reovirus is a promising oncolytic virus, acting by both direct and immune-mediated mechanisms, although its potential may be limited by inactivation after systemic delivery. Our study addressed whether systemically delivered reovirus might be shielded from neutralising antibodies by cell carriage and whether virus-loaded blood or hepatic innate immune effector cells become activated to kill colorectal cancer cells metastatic to the liver in human systems. We found that reovirus was directly cytotoxic against tumour cells but not against fresh hepatocytes. Although direct tumour cell killing by neat virus was significantly reduced in the presence of neutralising serum, reovirus was protected when loaded onto peripheral blood mononuclear cells, which may carry virus after intravenous administration in patients. As well as handing off virus for direct oncolytic killing, natural killer (NK) cells within reovirus-treated blood mononuclear cells were stimulated to kill tumour targets, but not normal hepatocytes, in a Type I interferon-dependent manner. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumour cells when activated by reovirus. Hence, intravenous reovirus may evade neutralisation by serum via binding to circulating mononuclear cells, and this blood cell carriage has the potential to investigate both direct and innate immune-mediated therapy against human colorectal or other cancers metastatic to the liver. What's new? Reovirus can deliver a double whammy to cancer: it hunts down and destroys ras-activated tumor cells, and it can also fire up the immune system against the tumor. The immune system, however, is a fickle ally; in addition to attacking tumor cells, an efficient immune response also rids the body of reovirus, hindering therapy. This study investigated whether therapeutic reovirus could be shielded from immune assault. They showed that loading reovirus onto blood mononuclear cells provides safe transportation to target cells, in this case, colorectal tumor cells, and the reovirus-loaded immune cells themselves also launch an attack against tumor cells. Reovirus appears to be a promising new avenue for cancer treatment.

AB - Reovirus is a promising oncolytic virus, acting by both direct and immune-mediated mechanisms, although its potential may be limited by inactivation after systemic delivery. Our study addressed whether systemically delivered reovirus might be shielded from neutralising antibodies by cell carriage and whether virus-loaded blood or hepatic innate immune effector cells become activated to kill colorectal cancer cells metastatic to the liver in human systems. We found that reovirus was directly cytotoxic against tumour cells but not against fresh hepatocytes. Although direct tumour cell killing by neat virus was significantly reduced in the presence of neutralising serum, reovirus was protected when loaded onto peripheral blood mononuclear cells, which may carry virus after intravenous administration in patients. As well as handing off virus for direct oncolytic killing, natural killer (NK) cells within reovirus-treated blood mononuclear cells were stimulated to kill tumour targets, but not normal hepatocytes, in a Type I interferon-dependent manner. Similarly, NK cells within liver mononuclear cells became selectively cytotoxic towards tumour cells when activated by reovirus. Hence, intravenous reovirus may evade neutralisation by serum via binding to circulating mononuclear cells, and this blood cell carriage has the potential to investigate both direct and innate immune-mediated therapy against human colorectal or other cancers metastatic to the liver. What's new? Reovirus can deliver a double whammy to cancer: it hunts down and destroys ras-activated tumor cells, and it can also fire up the immune system against the tumor. The immune system, however, is a fickle ally; in addition to attacking tumor cells, an efficient immune response also rids the body of reovirus, hindering therapy. This study investigated whether therapeutic reovirus could be shielded from immune assault. They showed that loading reovirus onto blood mononuclear cells provides safe transportation to target cells, in this case, colorectal tumor cells, and the reovirus-loaded immune cells themselves also launch an attack against tumor cells. Reovirus appears to be a promising new avenue for cancer treatment.

KW - colorectal liver metastases

KW - interferon-dependent

KW - NK cells

KW - reovirus

UR - http://www.scopus.com/inward/record.url?scp=84874937343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874937343&partnerID=8YFLogxK

U2 - 10.1002/ijc.27918

DO - 10.1002/ijc.27918

M3 - Article

C2 - 23114986

AN - SCOPUS:84874937343

VL - 132

SP - 2327

EP - 2338

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -